Enwei Pharmaceutical Co Ltd
SZSE:301331
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (7.3), the stock would be worth ¥27.91 (5% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7 | ¥26.71 |
0%
|
| 3-Year Average | 7.3 | ¥27.91 |
+5%
|
| 5-Year Average | 7 | ¥26.69 |
0%
|
| Industry Average | 23.9 | ¥91.68 |
+243%
|
| Country Average | 28.8 | ¥110.54 |
+314%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
E
|
Enwei Pharmaceutical Co Ltd
SZSE:301331
|
758.4m CNY | 7 | 14.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 28.3 | 41.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 16.9 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.5 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.1 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 9.7 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 7.5 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 7.1 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Enwei Pharmaceutical Co Ltd
Glance View
Enwei Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of proprietary Chinese and chemical medicines. The company is headquartered in Chengdu, Sichuan and currently employs 1,610 full-time employees. The company went IPO on 2022-09-21. The firm focuses on gynecological products, pediatric medicines, respiratory medicines and other fields. The firm's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules and Danxiong Tongmai granules. Its products are mainly sold through direct sales and e-commerce. The firm principally conducts its businesses in the domestic market.
